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Bile bilirubin pigment analysis in disorders of
bilirubin metabolism in early infancy
W S Lee, P J McKiernan, S V Beath, M A Preece, D Baty, D A Kelly , B Burchell,
D J Clarke
Abstract
Background—Early and accurate diagno-
sis of Crigler–Najjar syndrome, which
causes prolonged unconjugated hyper-
bilirubinaemia in infancy, is important, as
orthotopic liver transplantation is the
definitive treatment.
Aim—To determine whether bilirubin
pigment analysis of bile in infants
with prolonged unconjugated hyperbili-
rubinaemia provides useful diagnostic
information in the first 3 months of
life.
Methods—Retrospective review of pa-
tients with prolonged unconjugated hy-
perbilirubinaemia referred to the liver
unit, Birmingham Children’s Hospital,
for the diagnosis of Crigler–Najjar syn-
drome. Bile bilirubin pigment composi-
tion was determined by high performance
liquid chromatography. Initial diagnoses
were made based on the result of bile
bilirubin pigment composition. Final
diagnoses were made after reviewing
the clinical course, response to pheno-
barbitone, repeat bile bilirubin pigment
composition analysis, and genetic
studies.
Results—Between 1992 and 1999, nine
infants aged less than 3 months of age with
prolonged hyperbilirubinaemia under-
went bile bilirubin pigment analyses.
Based on these, two children were diag-
nosed with Crigler–Najjar syndrome
(CNS) type 1, six with CNS type 2, and one
with Gilbert’s syndrome. Five children
whose initial diagnosis was CNS type 2
had resolution of jaundice and normalisa-
tion of serum bilirubin after discontinuing
phenobarbitone, and these cases were
thought to be normal or to have Gilbert’s
syndrome. One of the initial cases of CNS
type 1 responded to phenobarbitone with
an 80% reduction in serum bilirubin con-
sistent with CNS type 2. In all, the
diagnoses of six cases needed to be
reviewed.
Conclusions—Early bile pigment analysis,
performed during the first 3 months of
life, often shows high levels of unconju-
gated bilirubin or bilirubin monoconju-
gates, leading to the incorrect diagnosis of
both type 1 and type 2 Crigler–Najjar syn-
drome.
(Arch Dis Child 2001;85:38–42)
Keywords: bile; bilirubin pigment analysis;
Crigler–Najjar syndrome; Gilbert’s syndrome
Unconjugated hyperbilirubinaemia is an im-
portant problem in the neonatal period. Com-
mon causes include physiological jaundice,
breast milk jaundice, overproduction (that is,
polycythaemia), systemic disease (congenital
hypothyroidism, sepsis), and inherited disor-
ders of bilirubin metabolism.1 These latter
include Crigler–Najjar syndrome (CNS) types
1 and 2—caused by a deficiency of hepatic uri-
dine diphosphate glucuronosyl transferase
(UGT) and characterised by high serum levels
of unconjugated bilirubin that appear in the
first few days after birth2—and Gilbert’s
syndrome.3
Accurate diagnosis of Crigler–Najjar syn-
drome is important because of the implications
for prognosis and treatment. Treatment of
CNS type 1 consists of the aggressive use of
measures to remove bilirubin (either photo-
therapy or exchange transfusion), while liver
transplantation is the definitive treatment.4 5
The major diVerentiating characteristic be-
tween the two types of Crigler–Najjar syn-
drome is the response to drugs that induce
activity of cytochrome P450 enzymes.6–8 Pheno-
barbitone (phenobarbital) causes a significant
decline in the serum bilirubin of patients with
type 2 disease, with increased hepatic clearance
of radiolabelled bilirubin and increased biliary
levels of bilirubin diglucuronides.6 8 9 However,
diVerentiating Crigler–Najjar syndrome type 1
from type 2 solely on the basis of response to
phenobarbitone can sometimes be mislead-
ing.10 DiVerentiation using bile bilirubin pig-
ment analysis has been recommended.11 12 In
CNS type 1, duodenal bile is practically devoid
of bilirubin conjugates. In CNS type 2,
bilirubin monoglucuronides are present and
some diglucuronides may be detectable during
treatment with phenobarbitone.11 12 In Gil-
bert’s syndrome, bilirubin diglucuronides are
the predominant pigment.11
The timing of the duodenal aspirate is
important. Subsequent management and prog-
nosis depend on an accurate diagnosis, and cli-
nicians are often under pressure to make an
early diagnosis. We have reviewed the eventual
outcome of children who had bile bilirubin
pigment analysis undertaken in early infancy,
in order to determine whether early pigment
analysis provides useful diagnostic infor-
mation.
Methods
We reviewed retrospectively those infants with
severe neonatal unconjugated hyperbilirubin-
aemia who were referred to the liver unit,
Birmingham Children’s Hospital, between
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1992 and 1999. Common causes of prolonged
unconjugated hyperbilirubinaemia were ex-
cluded by the referring clinicians. Basic demo-
graphic data, family history, onset of jaundice,
peak serum bilirubin, and clinical response to
phenobarbitone treatment were obtained from
the case notes. Abdominal ultrasound and liver
biopsies were performed when clinically indi-
cated. The final diagnosis was made on the
basis of a combination of results of bile
bilirubin pigment analysis, genetic studies,
clinical course, and response to phenobarbi-
tone.
COLLECTION OF BILE AND BIOCHEMICAL
ANALYSES
Phototherapy was suspended at least 24 hours
before the collection of bile pigment. Bile was
collected during upper gastrointestinal endos-
copy. The secretion of bile into the duodenum
was facilitated by intravenous injection of 1–2
units/kg of cholecystokinin, and 2–5 ml of bile
were extracted from the duodenum. The bile
aspirates obtained were immediately shielded
from light, frozen with liquid nitrogen, and
stored at −80°C. The bilirubin pigment
composition of the bile was determined by high
performance liquid chromatography (HPLC)
analysis of native tetrapyrolles of unconjugated
bilirubin and bilirubin glucuronides at the
department of molecular and cellular pathol-
ogy, Ninewells Hospital, Dundee, Scotland,
and the Division of Biological Sciences,
University of Huddersfield, England, as previ-
ously described.13
The reference ranges of bile bilirubin
pigments for normal subjects were: unconju-
gated 0–2%, monoglucuronides 7–16%, diglu-
curonides 79–91%. Analysis showed that
exposure of bile samples to the light source
used during the endoscopy procedure had no
significant eVect on the measured composition
of bilirubin pigments (Clarke DJ, Burchell B,
unpublished data). Initial diagnosis of Crigler–
Najjar syndrome type 1 or type 2 or Gilbert’s
syndrome was made according to the bile
bilirubin pigment composition.11
GENETIC STUDIES
Genetic studies for Crigler–Najjar syndrome
and Gilbert’s syndrome were performed as
previously described.3 14 Whole blood was
obtained and DNA extracted. A homozygosity
for a (TA)7TAA (TA7/TA7) has been associ-
ated with Gilbert’s syndrome.14 Crigler–Najjar
syndrome types 1 and 2 were diagnosed when
there was homozygosity or double heterozygos-
ity for known mutations.
Results
During the period of 1992 to 1999, nine
infants aged less than 3 months with severe
unconjugated hyperbilirubinaemia were re-
ferred to the hepatology unit, Birmingham
Children’s Hospital, for further diagnosis.
There were five boys and four girls. Eight were
delivered at term, while case No 6 was
delivered at 36 weeks. Six were white (Europid)
and three were born to consanguineous Asian
parents originating from the Indian subconti-
nent. There was no family history of severe
neonatal jaundice.
All infants had onset of severe jaundice
within first week of life (median 3 days). The
peak serum bilirubin ranged from 300 to 650
µmol/l (median 396 µmol/l). All required pho-
totherapy, while case No 8 had double
exchange transfusions. Four cases (cases 2, 6,
7, and 9) were started on phenobarbitone at 5
mg/kg body weight by their referring clinicians.
Five cases were breast fed (cases 3, 4, 5, 7, and
8). Case 5 had an atrioventricular septal defect.
Three cases (cases 1, 2, and 3) had liver biopsy
as part of the diagnostic workup. All were
reported as normal histologically.
BILE BILIRUBIN PIGMENT ANALYSIS
The bile bilirubin pigment analyses were
performed between ages of 10 and 58 days
(median 25 days) (table 1). Based on the
results of analyses (first analysis in case 3),
there were two infants with CNS type 1, six
with CNS type 2, and one with Gilbert’s
syndrome. Case No 3 had two analyses. The
second analysis was carried out seven months
after the first, while the patient was treated with
phenobarbitone and when the serum bilirubin
Table 1 Demographic data, peak serum bilirubin, and results of bile bilirubin pigment analysis in nine children with prolonged and severe unconjugated
hyperbilirubinaemia
Case
No Sex Ethnicity*
Onset of
jaundice (days)
Peak SB
(µmol/l)
Conjugated
SB (µmol/l)
UC bilirubin
(µmol/l)
Age of bile
analysis (days) PB
UC (%)
(0–2)†
MC (%)
(7–16)†
DC (%)
(79–91)† Diagnosis‡
1 M European 1 431 0 431 19 − 100 0 0 CNS 1
2 F European 4 396 2 394 38 + 19 81 0 CNS 2
3 M Asian 3 650 10 640 25 − 100 0 0 CNS 1
8 m¶ + 1 91 8
4 M European 2 300 0 300 25 − 2 34 64 Gilbert
5 F Asian 1 456 20 436 18 − 36 57 7 CNS 2
6 F European 6 390 10 380 33 + 4 64 31
7 M European 2 340 20 320 58 + 25 46 29
8 M European 5 >500 0 >500 10 − 20 53 27
9 F Asian 4 389 19 380 41 + 43 26 31
10 M European 5 – – – 13 y − 1 18 82
11 F European 2–3 y – – – 16 y − 4 18 78
12 M European 5 403 20 383 13 y + 14 80 5
13 M European 16 y 63 21 52 16 y − 12 70 18
*The three Asians infants were born to consanguineous parents.
†Reference range for normal individuals (Clarke DJ, Burchell B, unpublished data).
‡Diagnoses based on analysis of bile bilirubin pigments.
¶Second analysis performed at 8 months of age while on phenobarbitone.
CNS 1, Crigler–Najjar type 1; CNS 2: Crigler–Najjar type 2; DC, bilirubin diglucuronides; m, months; MC, bilirubin monoglucuronides; PB, phenobarbitone treat-
ment during bile bilirubin analysis (+, on phenobarbitone, −, not on phenobarbitone); SB, serum bilirubin; UC, unconjugated; y, years.
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had fallen to 80 µmol/l. There was a marked
reduction in the unconjugated bilirubin with a
substantial increase in the monoglucuronides.
For comparison, the results of bile bilirubin
pigment analysis of four patients older than 3
months, who were referred to the liver unit for
investigations of the underlying cause of
jaundice, are also shown in table 1. Cases 10
and 11 were investigated for intermittent jaun-
dice, with a clinical diagnosis of Gilbert’s
syndrome. Case 12 was diagnosed clinically as
CNS type 2 with persistent jaundice. The
serum bilirubin was 150 µmol/l, mainly uncon-
jugated while on phenobarbitone. Case 13 was
first noticed to be jaundiced at the age of 16,
after an episode of acute gastroenteritis. The
serum bilirubin was 63 µmol/l, with unconju-
gated bilirubin 52 µmol/l.
GENETIC STUDIES
Genetic studies were performed in four cases
(cases 1, 2, 8, and 9). Two cases (case 8 and 9)
were homozygous UGT1A1 TA6/TA6, which is
not associated with hyperbilirubinaemia. Case
1 showed a heterozygous G-to-C mutation in
exon 2 at nucleotide position 923 of the
UGT1A1 gene, which results in a glycine to
alanine change at codon 308. A second hetero-
zygous mutation was found where there was a
T residue deletion at nucleoside 1221
(1221delT) in exon 4. Case 1 has inherited two
defective UGT1A1 alleles from each parents,
resulting in complete loss of bilirubin UGT
activity and CNS type 1. Case 2 showed a het-
erozygous C-to-T mutation at nucleotide posi-
tion 625 of the UGT1A1 gene and a hetero-
zygous IVS4-1G-to-A mutation. In addition
she is also heterozygous for UGT1A1 promoter
alleles TA6/TA7. Neither TA6/TA6 nor TA6/
TA7 are known to be associated with hyper-
bilirubinaemia.
CLINICAL COURSE AND EVENTUAL DIAGNOSES
These data are shown in table 2. Diagnosis of
six cases needed to be reviewed. Case 3, with
unconjugated bilirubin and no mono- or diglu-
curonides in the bile, was initially diagnosed as
CNS type 1. Phenobarbitone was started and
phototherapy was continued. Serum bilirubin
fell to 40–60 µmol/l, and the duration of
phototherapy shortened progressively. A sec-
ond bile bilirubin pigment analysis, performed
at 8 months of age, showed predominantly
monoglucuronides. The diagnosis was revised
to CNS type 2. Presently, at 5 years of age, the
serum bilirubin is maintained in the range of
50–90 µmol/l while on phenobarbitone.
Five cases (cases 5, 6, 7, 8, and 9), which had
an initial diagnosis of CNS type 2, had resolu-
tion of jaundice and a fall in serum bilirubin
following treatment with phenobarbitone.
They have all had normal serum bilirubin since
discontinuation of phenobarbitone. In addi-
tion, both case 8 and case 9 had negative
genetic studies for the Crigler–Najjar syn-
drome mutation and Gilbert’s syndrome (TA6/
TA6). Case 6, who belonged to a travelling
family, was given phenobarbitone for one week.
The serum bilirubin continued to fall after
phenobarbitone was discontinued. The final
diagnosis was thought to be physiological jaun-
dice or Gilbert’s syndrome. In contrast, in all
the four cases who had bile bilirubin pigment
analysis done after 3 months of age, the
diagnosis that was made on the basis of the
results of bile bilirubin pigment analysis
concurred with the clinical diagnosis.
Discussion
The diagnosis of Crigler–Najjar syndrome types
1 and 2 and Gilbert’s syndrome can usually be
made from a combination of response to pheno-
barbitone, bile bilirubin pigment analysis, and
genetic studies.15 In vitro measurement of UGT
activity in liver biopsy tissue to diVerentiate
CNS type 1 from CNS type 2 is complex and
not routinely available.16 Phenobarbitone treat-
ment reduces serum bilirubin by 26% or more
in CNS type 2, while no reduction occurs in type
1.11 However, there are some exceptions to this
observation,16 and in addition, the reduction in
serum bilirubin may not be apparent within a
few months after starting treatment.10
Sinaasappel et al performed bile bilirubin
pigment analysis in nine patients with Crigler–
Najjar syndrome (four type 1 and five type 2),
aged between 1 and 18 years, and concluded
that the two types could be diVerentiated on
Table 2 Initial diagnosis, response to phenobarbitone, genetic studies, and final diagnosis
Case Initial diagnosis Response to PB Genetic studies Follow up and outcome Final diagnosis
1 CNS 1 None a Phototherapy 10 h/day; awaiting liver
transplant
CNS 1
2 CNS 2 Good b On PB; SB ∼78–139 µmol/l CNS 2
3 CNS 1 Good Phototherapy discontinued at 1 year; SB
∼90–110 µmol/l while on PB
CNS 2
4 Gilbert Good PB for 1 week; SB 33 µmol/l while not on PB Gilbert
5 CNS 2 Good Not on PB, SB 9 µmol/l Gilbert/normal?
6 CNS 2 Good SB normalised after stopping PB Gilbert/normal?
7 CNS 2 Good PB × 14 d; SB 17 µmol/l 3 months after
discontinuing PB
Gilbert/normal?
8 CNS 2 Good cTA6/TA6 SB 10 µmol/l after discontinuing PB Normal
9 CNS 2 Good TA6/TA6 Clinically not jaundiced, not on PB Normal
10 Gilbert TA6/TA7d Not on PB Gilbert
11 Gilbert Not on PB Gilbert
12 CNS 2 Good On PB, PB 150 µmol/l CNS 2
13 Gilbert Not on PB Gilbert
aDouble heterozygous: G→C mutation at nucleoside 923 of exon 2 of UGT 1A1, and T residue deletion at nucleoside 1221 at exon 4.
bHeterozygous for C→T mutation at nucleoside 625 of exon 1 of UGT 1A1.
cNegative for CNS mutation in addition to homozygous TA6/TA6, which is not associated with Gilbert’s syndrome.
dFather, paternal grandmother, and uncle have TA7/TA7, which has been associated with Gilbert’s syndrome.
CNS 1, Crigler–Najjar syndrome type 1; CNS 2, Crigler–Najjar syndrome type 2; PB, phenobarbitone; SB, serum bilirubin.
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the basis of bile bilirubin pigment analysis.11
However, such a delay in confirming the diag-
nosis is unacceptable in clinical practice, as cli-
nicians usually face enormous pressure from
parents to confirm or exclude the possibility of
CNS type 1, especially in view of the eventual
need for a liver transplant. Hence it would
seem reasonable to perform bile bilirubin
pigment analysis at a much younger age, espe-
cially during early infancy, when the majority
of patients would still have significant jaundice.
However, before recommending routine
analysis of bile bilirubin pigments in early
infancy, the eVect of maturation of UGT
needed to be considered. Ciotti et al observed a
delayed response to phenobarbitone in a child
with CNS type 2, who was initially diagnosed
as type 1 because of non-response to phenobar-
bitone for the first 7 months of life.10 They
attributed such delay to a simple developmen-
tal phenomenon, causing slow development of
the secondary structural changes necessary for
UGT activity. Such a developmental phenom-
enon could explain the observations made in
this study that bile bilirubin pigment analysis
performed early in life showed low levels of
unconjugated bilirubin and monoglucuronides
in the bile because of relatively low activity of
the enzyme UGT. With maturation and the
introduction of phenobarbitone, the process of
glucuronidation increased and the serum
bilirubin fell. Rubaltelli et al observed that with
phenobarbitone treatment there was an abso-
lute increase in the monoglucuronide concen-
tration but not the diglucuronide concentra-
tion in the bile.12 We observed that in case 3,
after phenobarbitone treatment, there was a
significant increase in both the mono- and
diglucuronides in the bile.
We have shown that while bile aspirate for
bilirubin pigment analysis can be performed
with relative ease and safety during the first 3
months of life, analysis of bile bilirubin pigment
at such a young age often showed high levels of
unconjugated or monoconjugated bilirubin in
the bile. As outlined above, this reflects the
immaturity of hepatocytes at a very young age,
leading to relative UGT deficiency. It has been
shown previously that UGT activity is low in
the neonatal period and increases gradually to
adult values after 3 months of age.17 This
immaturity had led to overestimation of the
severity of the disease and an overdiagnosis of
the Crigler–Najjar syndrome, both type 1 and
type 2, in our cases. A subsequent review of the
initial diagnoses was necessary in six of nine
instances. In five cases, normalisation of serum
bilirubin after discontinuation of phenobarbi-
tone made the diagnosis of CNS type 2 unlikely.
In case 3, who had had two analyses of bile
bilirubin pigments, the second analysis showed
a marked increase of bilirubin monoglucuro-
nides and reduced unconjugated bilirubin
compared with the first analysis, which con-
sisted of predominantly unconjugated bilirubin.
In case 2, whose initial diagnosis of CNS
type 2 concurred with the final diagnosis, bile
bilirubin pigment analysis was performed when
the patient was on phenobarbitone. In case
3—who had a second bile bilirubin analysis
that showed predominantly a monoglucuro-
nide, consistent with the clinical picture of
CNS type 2—the bile bilirubin pigment analy-
sis was performed after phenobarbitone was
started. It would therefore be reasonable to
recommend performing bile bilirubin pigment
analysis while the patient is on phenobarbitone.
In has been shown convincingly that muta-
tions in the UGT1 gene—the gene locus encod-
ing the enzyme UGT in patients with CNS type
1—are responsible for abolishing the hepatic
UGT activity in vitro in COS cells.18 Mutation
analysis for both Crigler–Najjar syndrome and
Gilbert’s syndrome is now available.19 This is
useful for confirmation of the clinical diagnosis
and for genetic counselling, but is complicated
and not routinely available.15 The only CNS
type 1 case in this series was shown to be a dou-
ble heterozygote for mutations responsible for
CNS type 1. In addition, two patients with ini-
tial diagnosis of CNS type 2, but who
subsequently had normal levels of serum
bilirubin without phenobarbitone, were found
to be homozygous of TA6/TA6, which is not
associated with Gilbert’s syndrome.
As a result of this study, we subsequently
reviewed the policy of investigating children
with prolonged unconjugated hyperbilirubin-
aemia. The protocol has been revised to avoid
performing bile bilirubin pigment analysis too
early and thereby overdiagnosing Crigler–
Najjar syndrome types 1 and 2. After excluding
other more common causes of unconjugated
hyperbilirubinaemia, a therapeutic trial of phe-
nobarbitone at a dose of 5 mg/kg body weight
should be started while continuing photo-
therapy if necessary (fig 1). Such patients
Figure 1 Proposed schematic investigation of prolonged unconjugated
hyperbilirubinaemia. SB, serum bilirubin.
Jaundiced
continue phenobarbitone
Perform bile bilirubin pigment analysis
consider genetic analysis
Not jaundiced
Stop phenobarbitone
repeat SB, at one week
Unconjugated hyperbilirubinaemia
(PB > 200 m mol/l, mainly unconjugated)
exclude common causes 
Start phenobarbitone (5 mg/kg body weight)
continue phototherapy if SB > 250 m mol/l
Regular review till three months
Jaundice recurs
No further action
Jaundice resolved
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should then be repeatedly reviewed; if by 3
months of age there is persistent elevation of
unconjugated serum bilirubin, vigorous treat-
ment with phototherapy and phenobarbitone
should be continued. Bile bilirubin pigment
analysis should be delayed until after 3 months
of age. Although genetic studies may be useful,
currently they are complex to perform and not
routinely available, but they can be done if
there is a particular concern.
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